Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells

International Journal of Cancer

Volumn 122, Issue 8, 2008, Pages 1891-1900

  Deubzer, Hedwig E ^a,b   Ehemann, Volker ^b   Westermann, Frank ^a   Heinrich, Ralf ^c   Mechtersheimer, Gunhild ^b   Kulozik, Andreas E ^b   Schwab, Manfred ^a   Witt, Olaf ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cell cycle arrest; Differentiation; E2F 1 regulated genes; Epigenetic therapy; RB tumor suppressor network

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; HELMINTHOSPORIUM CARBONUM TOXIN; HISTONE DEACETYLASE INHIBITOR; MYCOTOXIN; TETRAPEPTIDE; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; ENZYME INHIBITOR; HISTONE DEACETYLASE; NANOCAPSULE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL VIABILITY; COCHLIOBOLUS CARBONUM; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA; TUMOR GROWTH; ACETYLATION; CANCER INVASION; CANCER STEM CELL; CELL CYCLE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HYPHOMYCETES; METABOLISM; NEUROBLASTOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELMINTHOSPORIUM; HISTONE DEACETYLASES; HUMANS; MYCOTOXINS; NANOCAPSULES; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 40349098104     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23295     Document Type: Article

References (43)

1. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, Stallings RL, Benoit Y, Renard M, De Paepe A, Laureys G, et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006;7:R84.
2. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80.
3. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004;430:797-802.
4. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett 2007;250:250-67.
5. Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull 2005;28:565-8.
6. Miller MA, Ohashi K, Zhu X, McGrady P, London WB, Hogarty M, Sandler AD. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group. J Pediatr Hematol Oncol 2006;28:412-17.
7. Westermann F, Henrich KO, Wei JS, Lutz W, Fischer M, Konig R, Wiedemeyer R, Ehemann V, Brors B, Ernestus K, Leuschner I, Benner A, et al. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status. Clin Cancer Res 2007;13:4695-703.
8. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR, III, Fallon RJ, Rescorla FJ. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg 2006;41:377-81.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
10. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
11. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
12. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
13. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
14. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 2001;20:6969-78.
15. Walton JD. HC-toxin. Phytochemistry 2006;67:1406-13.
16. Brosch G, Ransom R, Lechner T, Walton JD, Loidl P. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell 1995;7:1941-50.
17. Hildmann C, Wegener D, Riester D, Hempel R, Schober A, Merana J, Giurato L, Guccione S, Nielsen TK, Ficner R, Schwienhorst A. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J Biotechnol 2006;124:258-70.
18. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell 1998;92:463-73.
19. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
20. de Veas RG, Schweigerer L, Medina MA. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in paediatric tumour cells. Effects of tumour cell proliferation modulators on gelatinolytic activity. J Cancer Res Clin Oncol 1995;121:275-8.
21. Witt O, Monkemeyer S, Ronndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, Pekrun A. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 2003;101:2001-7.
22. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
23. Raza A, Preisler H, Lampkin B, Lykins J, Kukla C, Gartside P, Sheikh Y, Yousuf N, White M, Barcos M, Bennett J, Browman G. Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia. Am J Hematol 1993;42:147-57.
24. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, Cheung NK, Ross RA. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004;6:838-45.
25. Hockfield S, McKay RD. Identification of major cell classes in the developing mammalian nervous system. J Neurosci 1985;5:3310-28.
26. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992;52:5334-41.
27. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation. and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
28. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 1982;68:589-96.
29. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-6.
30. Villabianca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995;13:894-901.
31. Joung KE, Kim DK, Sheen YY. Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells. Arch Pharm Res 2004;27:640-5.
32. Kamitani H, Taniura S, Ikawa H, Watanabe T, Kelavkar UP, Eling TE. Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma. Carcinogenesis 2001;22:187-91.
33. Min KN, Cho MJ, Kim DK, Sheen YY. Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells. Arch Pharm Res 2004;27:554-61.
34. Cinatl J Jr, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Komhuber B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 1996;7:766-73.
35. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.
36. Tannock IF. Cellular and molecular basis of oncology. In: Tannock IF, editor. The basic science of oncology. New York: McGraw-Hill, 1998. 350-69.
37. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 2006;12:5118-28.
38. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007;99:1107-19.
39. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
40. Ouwehand K, de Ruijter AJ, van Bree C, Caron HN, van Kuilenburg AB. Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. FEBS Lett 2005;579:1523-8.
41. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001;61:3591-4.
42. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62:6108-15.
43. Subramanian C, Opipari AW Jr, Bian X, Castle VP, Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102:4842-7.